Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?

Core Insights - Rigel Pharmaceuticals (RIGL) had a strong performance in 2025, with preliminary figures indicating significant growth driven by its lead drug Tavalisse and oncology assets [1][10] Financial Performance - Full-year 2025 product sales are projected to increase by 60% year-over-year to $232 million, surpassing previous guidance of $225-$230 million [2] - Tavalisse generated $158.9 million in sales for 2025, marking a 52% increase year-over-year and accounting for over half of the company's total revenue [3] - The oncology drugs Gavreto and Rezlidhia contributed $42.1 million and $31 million in quarterly sales, respectively, enhancing Rigel's revenue diversification [4] - For 2026, Rigel anticipates net product sales between $255 million and $265 million, indicating continued growth [5] Competitive Landscape - Rigel faces significant competition in its target markets, particularly from Sanofi's BTK inhibitor Wayrilz, which poses a threat to Tavalisse [6][7] - Gavreto competes against Eli Lilly's Retevmo in the RET fusion-positive non-small cell lung cancer and advanced thyroid cancer markets [8] Valuation and Estimates - Rigel's stock is trading at a slight premium to the industry, with a price-to-sales (P/S) ratio of 2.41 compared to the industry average of 2.28 [11] - EPS estimates for 2025 and 2026 have seen upward revisions in the past 30 days, reflecting positive market sentiment [13]